Drug intelligence / Profile preview

rhubarb ethyl acetate extract

Development stage: Preclinical
Administration: Oral

Overview

**Rhubarb ethyl acetate extract** is a plant-derived mixture obtained from the roots or aerial parts of rhubarb species (e.g., Rheum emodi, Rheum ribes) using ethyl acetate as a solvent extraction phase. It is characterized by a high content of phenolic compounds—including gallic acid, catechin, and flavonoids—and is notable for potent antioxidant activity and enzyme inhibition, particularly amylase inhibition. The extract is investigated for health-promoting properties, with demonstrated strong radical scavenging activity and potential applications in medicine and food. Some preparations aim to enhance liver-protective and gallbladder-promoting effects while reducing the hepatotoxic anthraquinone content[1][2][4][5].

Other names: rhubarb ethyl acetate fraction

Targets

AMY (Pancreatic alpha-amylase)

Beyond the preview

Go deeper on rhubarb ethyl acetate extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rhubarb ethyl acetate extract.

Explore the full profile